In the present study, we performed characterization of circulated CD3+CD4+ and CD3+CD8+ T-cells in the blood of newly diagnosed ES-SCLC patients treated with immunotherapy on the front line. The gene discussed is CD4; the disease is small cell lung carcinoma.